PMP-DEGESCO: Validation of a precision medicine tool based on online cognitive evaluation, genetic risk stratification and bloodbased biomarkers for the identification of preclinical Alzheimer's Disease

Resumen del proyecto

Medical problem: create a global strategy for identifying AD cases in targeted populations at the early stages of disease development (prodromal and preclinical cases of AD). This unmet medical is becoming more pressing considering the imminent arrival of disease-modifying drugs.Rationale and study design:This proposal consists of launching a web-based nationwide platform for testing Precision Medicine tools. We propose a multi-step strategy successively incorporating precision medicine techniques into diagnostic algorithms.Methods:14 Memory clinics/8CCAA will participate in building 2 cohorts with enriched sub-cohorts. 1)"PMPDEGESCO online cohort"(n=50000) that will allow us to explore the use of digital cognitive tests, genetic risk scores and plasma AD biomarkers in targeted populations through a web tool 2) "Clinical validation cohort" with in-depth examination and CSF analysis as the gold standard (n=1000). Expected results: We aim to provide our National Health System with an instrument to:1)Improve the detection of individuals with prodromal AD (mild cognitive impairment).2)Allow the identification of individuals with preclinical and very early prodromal AD permitting secondary prevention once available disease-modifying drugs.3)Identify healthy individuals with a high genetic risk of AD, which will be instrumental for future targeted primary prevention strategies. Feasibility: This project builds upon DEGESCO's successful track record in AD research. Together with our expertise in genetics and clinics, we bring together the leading experts in neuroimaging, digital, and biological markers from Spain. DEGESCO is a consorti that has produced large-scale studies over the last decade. Our main achievements are 1)GWAS study with AD representing the largest sample (n>24,000) in our country for any chronic disease 2)Co-discovery of 80% of known AD genes and 3)Constructing Polygenic Risk Scores(PRS) with effects in the risk, pathology and endophenotypes of AD

Palabras clave

Genome wide association
polygenic risk score
Alzheimer's disease
Plasma biomarkers
digital markers
citizen sciences
preclinical diagnosis

Convocatoria

Acción Estratégica en Salud (AES)

Periodo de ejecución

01/01/2023 - 30/06/2026

Investigador Principal

PASCUAL, SANCHEZ JUAN

Centro beneficiario

FUNDACION CENTRO DE INVESTIGACION ENFERMEDADES NEUROLOGICAS (CIEN)

Centro de realización

FUNDACION CENTRO DE INVESTIGACION ENFERMEDADES NEUROLOGICAS (CIEN)

Comunidad Autónoma

MADRID

Provincia

MADRID

Financiación

2,479,550 €